세계의 이식 진단 시장 규모는 2024년에 9억 3,928만 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 18억 200만 달러에 달하며, 2025-2033년에 7.13%의 CAGR을 보일 것으로 예측하고 있습니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 약 34.6%의 큰 시장 점유율을 차지할 것으로 예측됩니다. 이 시장은 장기 이식 증가와 이식 적합성을 확인하고 이식 후 상태를 추적하기 위한 정확하고 신속한 비침습적 진단 시스템에 대한 수요 증가로 인해 활성화되고 있습니다. 또한 분자진단학, 차세대 염기서열 분석, 바이오인포매틱스의 발전은 기증자와 수혜자의 적합성, 거부반응의 위험성, 감염 추적을 강화하는 데 기여하고 있습니다. 또한 의료비 지출 증가와 정부 지원 프로그램이 이식 진단 시장 점유율을 더욱 높이고 있습니다.
이 시장은 비침습적 검사법의 발전, 맞춤형 의료의 채택 증가, 의료 인프라에 대한 투자 증가에 의해 주도되고 있습니다. 또한 각국의 헬스케어에 대한 정부 지출 증가가 시장 확대의 원동력이 되고 있습니다. 한 업계 보고서에 따르면 2021년 세계 의료비 지출은 사상 최고치인 9조 8,000억 달러에 달하고, 세계 GDP의 10.3%를 차지할 것으로 예상했습니다. 이와 더불어 장기 기증에 대한 인식이 높아지면서 국제보건기구의 지원책과 함께 이식 수술에 대한 폭넓은 접근을 촉진하고 있습니다. 또한 진단 워크플로우에 인공지능을 통합하여 거부반응 위험의 예측 정확도를 높이고 있습니다. 또한 진단 기업 및 의료 서비스 프로바이더와의 전략적 제휴를 통해 기술 혁신을 더욱 가속화하여 전 세계 이식 프로그램에서 정확하고 비용 효율적이며 확장 가능한 검사 솔루션을 사용할 수 있도록 하고 있습니다.
미국에서는 강력한 규제 프레임워크, 높은 의료비 지출, 최첨단 진단 기술의 광범위한 도입이 시장을 주도하고 있습니다. 또한 첨단 검사 능력을 갖춘 전문 이식센터가 존재하여 신속하고 신뢰할 수 있는 적합성 검사가 가능합니다. 이식 진단 시장의 새로운 동향 중 하나는 고부가가치 분자 및 유전체 분석의 사용을 장려하는 유리한 보험 적용 및 상환 정책의 확대입니다. 이와는 별도로 장기 기증을 촉진하는 지원책과 모델이 개발을 지원하고 있습니다. 예를 들어 2024년 11월, 메디케어 및 메디케이드 서비스 센터(CMS)는 신장 이식 접근성 개선, 치료의 질 향상, 치료 연계 최적화, 격차 해소, 메디케어 비용 절감을 목표로 하는 6년간의 강제적 장기 이식 접근성 증가(IOTA) 모델을 최종 결정했습니다. 이 모델은 2025년 7월 1일에 시작될 예정이며, 103개 신장 이식 병원이 참여하여 이식 건수 증가, 보다 신속하고 효율적인 장기 기증 수용, 이식편 생존율 향상을 장려하기 위해 성과에 따른 금전적 인센티브와 페널티를 채택할 예정입니다.
고령자 확대
세계에서 노인 인구 증가는 시장에 큰 성장 기회를 가져다주고 있습니다. 고령 환자는 노화와 관련된 퇴행성 질환이나 심혈관질환, 신부전, 간질환 등 만성질환의 위험이 높아 장기 이식이 필요한 경우가 많습니다. 한 업계 보고서에 따르면 65세 이상 성인의 약 93%가 적어도 한 가지 이상의 만성질환을 앓고 있다고 합니다. 약 79%가 2개 이상의 만성질환을 앓고 있습니다. 또한 수술 방법 및 수술 후 관리의 개선으로 고령의 환자도 이식이 가능해져 잠재적 후보자가 증가하고 있습니다. 노인의 면역체계는 특별한 문제가 있으며, 적합성을 판단하고 거부반응의 위험을 효과적으로 제어하기 위해서는 정확하고 진보된 진단이 필요합니다. 또한 이식 전후의 분자 검사 및 바이오마커 기반 모니터링은 이러한 집단에서 최적의 치료를 달성하기 위해 특히 중요합니다. 전 세계에서 수명이 길어짐에 따라 의료 시스템은 고령층의 장기 이식에 대한 수요가 증가하고 있으며, 이는 노인 환자 관리의 복잡성에 부합하는 정확하고 효과적이며 신속한 이식 진단 솔루션에 대한 수요를 직접적으로 증가시키고 있습니다.
만성질환 증가
가공식품의 소비 증가와 흡연 및 음주 인구 증가로 인해 급성 및 만성질환의 유병률이 증가하고 있으며, 장기부전 환자 수가 크게 증가하고 있습니다. 이는 이식 진단 시장 전망에 긍정적인 영향을 미치고 있습니다. 보고서에 따르면 만성질환의 부담은 2030년까지 약 47조 달러에 달할 것으로 예측됩니다. 또한 만성신장병, 간경화, 심부전 등의 질환은 말기 장기부전까지 진행되는 경향이 있으며, 이식이 가장 유력한 치료 옵션입니다. 이러한 만성질환의 유병률 증가는 영양부족, 운동부족, 과체중 및 비만과 같은 생활습관 선택, 당뇨병 및 고혈압 증가와 상관관계가 있습니다. 모든 이식 과정에서는 환자에게 최상의 결과를 제공하기 위해 HLA 타이핑, 교차 매칭, 면역 모니터링 등 이식 전후에 광범위한 진단 평가가 이루어집니다. 만성질환 부담 증가는 이식 후보자의 수를 증가시킬 뿐만 아니라 적합성 검사를 강화하고 장기 거부반응의 가능성을 최소화하며 다양한 유형의 장기 장기 이식편의 장기 생존율을 극대화하기 위해 정교한 분자 및 혈청학적 검사 기술의 도입으로 이어지고 있습니다.
심각해지는 교통사고 건수
심각한 교통사고 발생 건수 증가는 사망한 기증자로부터 장기를 얻을 수 있는 가능성을 높여 간접적으로 이식 진단 시장의 성장에 기여하고 있습니다. 업계의 보고에 따르면 교통사고로 인해 매년 전 세계에서 약 119만 명이 목숨을 잃고 있습니다. 외상성 뇌손상이나 사망 사고로 인해 장기 기증이 가능한 경우가 많으며, 이는 증가하는 이식 수요를 충족시키는 데 필수적입니다. 이러한 사례에서 장기 기증이 가능해지면, 엄격한 시간 내에 기증자-수혜자 적합성을 판단하기 위해 신속하고 신뢰할 수 있는 진단 검사가 즉각적으로 필요합니다. 또한 실시간 PCR, 차세대 시퀀싱, 첨단 교차 매칭 분석 등의 기술은 정확한 적합성을 보장하고 거부반응의 위험을 줄이는 데 중요한 역할을 하고 있습니다. 여기에 더해 사고율이 높은 지역에서는 장기 조달 시스템이 탄탄하게 구축되어 있는 경우가 많아 이식 진단의 이용이 더욱 가속화되고 있습니다. 장기 부족이 여전히 전 세계적인 문제로 대두되고 있는 가운데, 안타깝게도 사망사고 증가는 이식 의료 분야에서 신속하고 정확한 진단 툴에 대한 수요를 부주의하게 지원하고 있습니다.
The global transplant diagnostics market size was valued at USD 939.28 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,802.00 Million by 2033, exhibiting a CAGR of 7.13% during 2025-2033. North America currently dominates the market, holding a significant market share of around 34.6% in 2024. The market is fueled by the increasing incidences of organ transplants and increasing demand for precise, fast, and non-invasive diagnostic systems to verify transplant compatibility and track post-transplant status. Furthermore, advances in molecular diagnostics, next-generation sequencing, and bioinformatics are facilitating enhanced detection of donor-recipient compatibility, risk of rejection, and infection tracking. Besides that, rising healthcare spending and supportive government programs are further augmenting the transplant diagnostics market share.
The market is propelled by advancements in non-invasive testing methods, increasing adoption of personalized medicine, and growing investments in healthcare infrastructure. Furthermore, the rising government spending on healthcare across numerous nations is driving market expansion. According to an industry report, global healthcare spending hit an all-time high of USD 9.8 Trillion in 2021, representing 10.3% of the global GDP. Besides this, rising awareness about organ donation, coupled with supportive policies from international health organizations, is fostering broader access to transplantation procedures. Additionally, the integration of artificial intelligence in diagnostic workflows is enhancing predictive accuracy for rejection risks. Also, strategic collaborations between diagnostic companies and healthcare providers are further accelerating innovation, ensuring the availability of precise, cost-efficient, and scalable testing solutions for global transplant programs.
In the United States, the market is driven by a strong regulatory framework, high healthcare spending, and extensive adoption of cutting-edge diagnostic technologies. Moreover, the presence of specialized transplant centers with advanced laboratory capabilities facilitates rapid and reliable compatibility testing. One of the emerging transplant diagnostics market trends is the expansion of favorable insurance coverage and reimbursement policies, which encourage the use of high-value molecular and genomic assays. Apart from this, supportive initiatives and models promoting organ donation are supporting market development. For instance, in November 2024, the Centers for Medicare & Medicaid Services (CMS) finalized the six-year mandatory Increasing Organ Transplant Access (IOTA) Model, aimed at improving access to kidney transplants, enhancing quality of care, optimizing care coordination, reducing disparities, and lowering Medicare costs. Scheduled to begin on July 1, 2025, the model will involve 103 kidney transplant hospitals and will employ performance-based financial incentives and penalties to encourage increased transplant volumes, faster and more efficient organ offer acceptance, and improved graft survival rates.
Expanding Geriatric Population
The global rise in the geriatric population is creating substantial growth opportunities for the market. Older patients are at higher risk of degenerative age-related conditions and chronic diseases like cardiovascular disease, renal failure, and liver disease, which often require transplantation of organs. According to an industry report, approximately 93% of adults aged 65 years and over suffer from at least one chronic illness. Approximately 79% suffer from two or more. Moreover, improved surgical methods and care after surgery have made transplantation increasingly possible for older patients, increasing the pool of potential candidates. The older immune system poses special challenges, with accurate and sophisticated diagnostics needed to determine compatibility and effectively control rejection risks. Additionally, pre- and post-transplant molecular testing and biomarker-directed monitoring are especially important in this population to achieve optimal therapy. With the increasing longevity of people worldwide, healthcare systems have been experiencing increased demand for organ transplantation among the elderly population, directly driving up the demand for accurate, effective, and speedy transplant diagnostic solutions compatible with the intricacies of geriatric patient management.
Rising Chronic Diseases
The growing prevalence of acute and chronic diseases on account of the increasing consumption of processed food products and the escalating number of individuals who smoke tobacco products and consume alcohol is causing a significant rise in the number of organ failure cases. This, in turn, is positively impacting the transplant diagnostics market outlook. According to reports, the burden of chronic diseases is projected to reach approximately USD 47 Trillion by 2030. Moreover, diseases like chronic kidney disease, cirrhosis, and heart failure tend to advance to end-stage organ failure, where transplantation is the most viable treatment option. This increased prevalence of chronic diseases correlates with lifestyle choices, such as poor nutrition, lack of activity, and overweight/obesity, and the increase in diabetes and hypertension. Every transplant process entails extensive pre- and post-transplant diagnostic evaluation, such as HLA typing, crossmatching, and immune monitoring, to provide the best possible outcomes for patients. The escalating chronic disease burden is not only increasing the number of transplant candidates but also leading to the implementation of sophisticated molecular and serological testing technologies in order to enhance compatibility testing, minimize chances of organ rejection, and maximize long-term graft survival rates for different types of organs.
Escalating Number of Severe Road Accidents
The rising incidence of severe road accidents is indirectly contributing to the transplant diagnostics market growth by increasing the availability of organs from deceased donors. As per industry reports, around 1.19 Million people lose their lives each year worldwide as a result of road accidents. Traumatic brain injuries and fatal accidents often result in viable organ donations, which are vital to meeting the growing demand for transplants. The availability of donor organs from such cases triggers the immediate need for fast and reliable diagnostic testing to determine donor-recipient compatibility within tight timeframes. Furthermore, technologies like real-time PCR, next-generation sequencing, and advanced crossmatching assays play a crucial role in ensuring accurate matching and reducing rejection risks. Besides this, regions with high accident rates often have robust organ procurement systems in place, further accelerating the use of transplant diagnostics. As organ shortages remain a global challenge, the unfortunate rise in fatal accidents is inadvertently sustaining the demand for rapid, high-precision diagnostic tools in transplant medicine.
Reagent and consumables lead the market in 2024. The segment constitutes the foundation of laboratory testing protocols. They are test kits, assay reagents, buffers, and disposable lab supplies utilized for HLA typing, crossmatching, and detection of antibodies. Their continual demand arises from the fact that every diagnostic test demands fresh and accurate materials for guaranteed accurate and reliable results, which have a direct bearing on transplant compatibility tests. As organ transplant success is highly dependent on reducing the risks of rejection, the quality and availability of such consumables are critical. Moreover, the increasing rate of transplant procedures being performed globally, along with the development of molecular and serological testing technology, fuels consistent market growth for these products. Suppliers are aided by a repeat business model, as the labs need to constantly restock, and the reagents and consumables are not only critical to clinical pathways but also a big revenue division in the market.
Molecular assay leads the market with around 42.6% of market share in 2024. They are precise, fast, and can identify genetic differences at a detailed level. Such tests, involving PCR-based techniques and next-generation sequencing (NGS), are extensively applied to HLA typing, donor-specific antibody detection, and monitoring post-transplant immune status. By confirming gene compatibility among donors and recipients with precise accuracy, molecular tests decrease organ rejection risk and enhance long-term graft survival. Their use is increasing as healthcare systems move toward more individualized and streamlined transplant evaluation processes. The technology's capability to rapidly handle complex genetic information aids in making timely decisions, important in transplant situations in which time sensitivity can determine patient outcomes. With ongoing developments, molecular assays are transforming the future of transplant diagnostics, rendering them invaluable in pre-transplant screening and post-transplant monitoring.
Kidney leads the market in 2024 due to the large prevalence of end-stage renal failure and chronic kidney disease globally. Timely and accurate diagnostics in this segment are critical to avoid incompatibility between the donor and recipient, minimize rejection risk, and maximize graft survival rates. These include tests like HLA typing, crossmatching, and detection of donor-specific antibodies, which are applied on a routine basis prior to and after kidney transplants, making diagnosis a part of the treatment process. Transplant diagnostics in kidney transplants are also bolstered by increased numbers of live and cadaveric donor transplants, as well as technology developed in molecular diagnostics that can furnish quicker and more accurate results. Since kidney transplants continue to be the most prevalent solid organ transplant, they are still a driving force for revenue and innovation in the market.
Pre-transplant diagnostics are critical to assess donor-recipient compatibility and reduce the threat of graft rejection. Such tests comprise HLA typing, crossmatch, and donor-specific antibody screening, all of which identify the optimal match prior to surgery. Precise pre-transplant evaluation increases the success rate of transplants, minimizes complications, and facilitates improved long-term outcomes. Infectious disease workup is also done in addition to compatibility testing to avoid transmission of infection during transplantation. The increase in organ transplant demand and organ unavailability renders accurate and efficient pre-transplant diagnostics essential for making timely decisions. Advances in molecular tests and automation further increase test accuracy and efficiency, reinforcing their role as a cornerstone step in the process of transplantation.
Post-transplant diagnostics target the surveillance of the recipient's immune reaction to identify early indicators of rejection or infection. The tests involved are donor-specific antibody measurement, biomarker determination, and molecular testing to determine the function of the graft and immune activity. Continuous post-transplant monitoring enables clinicians to modulate immunosuppressive therapy early in the course of disease, averting irreversible transplanted organ damage. The increased uptake of non-invasive and quick testing technologies enhanced the comfort of patients and facilitated more regular monitoring, resulting in improved long-term graft survival rates. Since organ rejection may take months or years to be observed following surgery, demand for trusted post-transplant diagnosis continues to be robust. Ongoing innovation in this space is broadening the capacity for earlier detection of complications and is an essential part of integrated transplant medicine.
Hospitals and transplant centers are one of the key end users as they have direct responsibility for patient evaluation, surgery, and post-operative care. Transplant centers depend on sophisticated diagnostic instrumentation to do HLA typing, crossmatching, and immune monitoring, maximizing donor-recipient compatibility and minimizing rejection. With the increasing number of transplant procedures globally, hospitals are increasingly implementing fast and precise molecular and serological diagnostic testing methodologies to enhance patient outcomes. Most transplant centers also have specialized laboratories within their premises, allowing for quicker turnaround times for urgent diagnostic results. Their place is not just pivotal in clinical decision-making but also in managing multidisciplinary teams, thereby a prime driver for demand in the transplant diagnostics market.
Research institutes and academic institutions are involved in the market by adding innovation, method development, and validation of novel testing methods. They are engaged in developing molecular assays, discovery of biomarkers, and genomic technology to make transplants more successful and minimize complications. They are also significantly involved in clinical trials to evaluate new diagnostic tools before using them in hospitals and commercial applications. Cooperation among scientific centers and industry players serves to convert the results of research into applicable diagnostic solutions. Besides, these companies equip medical specialists and scientists with training, thereby providing the transplant community with a qualified workforce. Their efforts lead to ongoing improvement in diagnostic precision, sensitivity, and economic efficiency, which further consolidates their place in the overall transplant diagnostics system.
Commercial service providers provide specialized transplant diagnostic tests on behalf of hospitals, transplant programs, and research institutions. These firms tend to have centralized labs with high-end technologies, allowing them to provide high-throughput and accurate testing services. With outsourcing to commercial vendors, healthcare facilities can obtain specialized knowledge and complex molecular tests without huge investments in infrastructure. This is highly beneficial for small centers with limited internal capabilities. Commercial vendors also help with quality assurance, compliance with regulations, and implementation of state-of-the-art technologies, including next-generation sequencing. Their efficiency, scalability, and capacity to work with numerous clients across regions make them a fundamental piece in bridging access to timely and reliable transplant diagnostics globally.
In 2024, North America accounted for the largest market share of over 34.6% driven by the region's robust healthcare infrastructure, intensive use of sophisticated diagnostic technologies, and significant presence of top industry players. Moreover, the high rate of organ transplant surgeries, fueled by increasing numbers of chronic illnesses like kidney and liver failure, provides a boost to the market. Transplant centers and hospitals in the US and Canada employ cutting-edge molecular assays, next-generation sequencing, and serological testing to provide precise donor-recipient matching as well as efficient post-transplant monitoring. Supportive reimbursement policies, government programs to encourage organ donation, and research collaborations continue to enhance the market. Furthermore, North America's emphasis on innovation and high clinical trial activity rate continues to fuel advances in transplant diagnostic techniques.
United States Transplant Diagnostics Market Analysis
In 2024, the United States holds a substantial share of around 88.70% of the transplant diagnostics share in North America. The market driven by a sharp rise in chronic diseases, particularly kidney failure, diabetes, heart conditions, and liver diseases, which is increasing the demand for organ transplants in top-tier medical centers nationwide. According to an industry report published in 2024, in the United States, an estimated 129 million individuals are affected by at least one major chronic illness, such as heart disease. Moreover, 42% suffer from two or more, while 12% suffer from as many as 5. Additionally, advancements in molecular diagnostics, particularly in the areas of human leukocyte antigen (HLA) typing and next-generation sequencing, have significantly improved donor-recipient matching and transplant outcomes, increasing the adoption of sophisticated diagnostic tools. Furthermore, growing awareness among healthcare professionals and patients about the importance of early and accurate diagnostic testing in transplantation is fueling market growth. The expansion of organ transplant programs and supportive government initiatives to improve transplant infrastructure have further heightened the need for reliable diagnostic systems. The presence of technologically advanced healthcare facilities and a favorable reimbursement environment are also contributing to increased diagnostic testing. Other than this, increased investments in research and development (R&D) by key market players are resulting in more accurate, faster, and cost-effective diagnostic tools.
Asia-Pacific Transplant Diagnostics Market Analysis
In Asia Pacific, the market is expanding due to the rapid expansion of healthcare infrastructure and transplant programs across the region, which is increasing access to crucial diagnostic testing. For instance, in March 2023, India's healthcare infrastructure comprises a total of 1,69,615 Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District Hospitals (DHs), and 362 Medical Colleges (MCs), spanning both urban and rural regions. Moreover, the increasing adoption of digital health technologies and laboratory automation, which enhance the efficiency and accuracy of diagnostic workflows, is also supporting industry expansion. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic platforms is also contributing to improved interpretation of complex genetic data, supporting more informed clinical decisions. Besides this, government support for transplant initiatives and favorable reimbursement policies in key nations are also encouraging the adoption of sophisticated testing systems.
Europe Transplant Diagnostics Market Analysis
The growth of the market in Europe is largely propelled by technological innovations and evolving healthcare policies. An increasing geriatric population and rising incidence of chronic conditions such as kidney disease, liver failure, and cardiometabolic disorders have heightened the demand for organ transplantation and associated diagnostics. According to reports, the number of individuals aged 65 years and older in the European Union accounted for 21.6% of the population of the region in January 2024. In parallel, breakthroughs in immunogenetics, advanced tissue typing platforms, and non-invasive biomarker assays are enabling more precise donor matching, early rejection detection, and optimal long term graft health. Increased awareness among clinicians and patients about the critical role of timely and accurate diagnostics in transplantation processes is also fueling uptake. Moreover, cross border healthcare initiatives and funding under pan European health programs are strengthening transplant networks, harmonizing diagnostic standards, and improving access across countries. A supportive reimbursement environment and alignment with personalized medicine strategies are also encouraging hospitals and laboratories to invest in sophisticated testing systems. Additionally, collaborative research efforts among academic institutions, biotech firms, and diagnostic companies are accelerating the commercialization of next generation assays tailored to European regulatory frameworks. The growing emphasis on quality metrics, audit compliance, and real world patient outcomes is further driving the adoption of standardized, high sensitivity diagnostic solutions.
Latin America Transplant Diagnostics Market Analysis
In Latin America, the market is significantly influenced by a growing focus on improving transplant success rates through personalized medicine and precision diagnostics. As healthcare systems strive to reduce post-transplant complications and improve long-term patient outcomes, there is an increasing demand for advanced immunological monitoring and molecular diagnostic tools. The gradual adoption of digital health and data integration technologies is also enhancing clinical decision-making and streamlining diagnostic processes. For instance, the digital health market in Brazil reached USD 10.66 Billion in 2024 and is projected to reach USD 40.85 Billion by 2033, growing at a CAGR of 16.10% during 2025-2033. Besides this, gradual enhancements in healthcare financing, insurance coverage, and reimbursement policies are making sophisticated transplantation diagnostics more accessible, supporting market growth.
Middle East and Africa Transplant Diagnostics Market Analysis
The market in the Middle East and Africa is experiencing robust growth due to the expansion of specialty healthcare facilities and the establishment of regional transplant centers catering to growing patient demand. Increasing investment in modern clinical laboratories is enabling access to advanced diagnostic methods such as immunogenetic profiling and multiplex biomarker assays. Governments in the region are also progressively prioritizing organ transplantation as part of national healthcare strategies, leading to improved funding and support for transplant-related services, including diagnostics. Additionally, the rising burden of non-communicable diseases, such as diabetes and hypertension, is leading to increased cases of organ failure and transplant need. An industry report indicates that the Middle East and North Africa region currently has 85 Million people living with diabetes, which is projected to rise to 163 million by 2050.
The market is characterized by intense innovations, led by the growing need for effective, timely, and non-invasive diagnostic products that can enhance patient outcomes in organ transplantation. Market players compete based on advancements in molecular diagnostics, next-generation sequencing (NGS), and polymerase chain reaction (PCR) technologies to deliver improvements in donor-recipient matching and post-transplant monitoring. Moreover, strategic partnerships with healthcare centers and research institutions are not uncommon, facilitating access to cutting-edge technology and increased global presence. In addition, regulatory compliance, quality control, and the capacity to deliver cost-efficient test solutions are foremost determinants of competitiveness. According to the transplant diagnostics market forecast, increasing transplant volumes, increasing knowledge of graft rejection detection in the early stage, and the incorporation of AI-powered data analytics are expected to sharpen competition between market players. Besides this, the emphasis on creating multiplex assays and custom testing solutions is opening new paths for differentiation, while regional growth strategies are being pursued to leverage emerging healthcare markets.